The study for transfer of Nicardipine to the fetus and neonate from mothers treated with Nicardipine. -Concentrations of Nicardipine in maternal and umbilical cord blood, and breast milk-

The study for transfer of Nicardipine to the fetus and neonate from mothers treated with Nicardipine. -Concentrations of Nicardipine in maternal and umbilical cord blood, and breast milk- - Placental transfer and disposition in breast milk of Nicardipine.

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000011792

Enrollment

Registered

2013-09-18

Start date

2011-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pregnancy-induced hypertension

Interventions

None listed

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Patients who is admitted to our institution for management of pregnancy induced hypertension and is administered Nicardipine either orally and/or intravenously to control the hypertension are included, and written informed consent is obtained. Normal pregnant women who is admitted to our institution for delivery and written informed consent is obtained.

Exclusion criteria

Exclusion criteria: Delivery before 22nd weeks of gestation (abortion). Multiple pregnancy Life threatening sever fetal anomaly and condition. Life threatening complication of the mother Patient delivered in other institution Positive screening for HBV, HCV and HIV

Design outcomes

Primary

Measure	Time frame
Concentration measured in maternal blood,Cord blood and breast milk,	—

Countries

Japan

Contacts

Public ContactHideyoshi Matsumura

Saitama Medical Center Department of Obstetrics and Gynecology(Center for Maternal , Fetal and Neonatal Medicine)

eisho@saitama-med.ac.jp049-228-3681

Outcome results